TABLE 2.

Univariable and multivariable Cox regression analyses in each patient cohort.

Variables		Univariate analysis			Multivariate analysis
		HR	95%CI	p-value	HR	95%CI	p-value
Discovery cohort
DNAMeFourLncSig	High vs. Low	2.45	1.69–3.56	2.3e−06	2.28	1.31–3.97	0.0038
Age	>60 vs. =60	1.05	0.73–1.5	0.8	1.13	0.7–1.83	0.62
Stage	III/IV vs. I/II	1	0.63–1.57	0.99	1.07	0.58–1.95	0.84
Grade	(III/IV vs. I/II)	1.08	0.73–1.62	0.69	1.65	0.96–2.84	0.068
Treatment response	CR vs. non-CR	0.16	0.09–0.29	6.6e−10	0.25	0.13–0.47	2.4e−05
Validation cohort
DNAMeFourLncSig	High vs. Low	2.06	1.35–3.16	0.00089	3.21	1.72–5.97	0.00024
Age	>60 vs. =60	1.51	1–2.28	0.049	2.13	1.2–3.79	0.01
Stage	III/IV vs. I/II	1.41	0.88–2.26	0.15	1.74	0.87–3.5	0.12
Grade	(III/IV vs. I/II)	0.79	0.51–1.23	0.3	1.07	0.59–1.96	0.82
Treatment response	CR vs. non-CR	0.2	0.1–0.4	3.8e−06	0.27	0.14–0.53	0.00015
TCGA cohort
DNAMeFourLncSig	High vs. Low	2.22	1.68–2.94	2e–08	2.53	1.69–3.79	5.9e−06
Age	>60 vs. =60	1.23	0.94–1.61	0.14	1.49	1.04–2.13	0.03
Stage	III/IV vs. I/II	1.22	0.88–1.69	0.23	1.43	0.91–2.25	0.12
Grade	(III/IV vs. I/II)	0.9	0.67–1.22	0.5	1.26	0.85–1.88	0.25
Treatment response	CR vs. non-CR	0.18	0.11–0.27	8e–15	0.24	0.15–0.37	5.9e−10